Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Julie R. Brahmer

ResearcherPublications, citations & collaboration network

Julie R. Brahmer is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 855 works, 125,633 citations, an h-index of 117 and an i10-index of 334.

855
Works
125,633
Citations
117
h-index
334
i10-index

How has Julie R. Brahmer's publication output changed over time?

ScholarIQpublication output · 2006–2019

Output grew100% over the shown period — from 1 works in 2006 to 2 in 2019.

1
1
2
2
1
3
2
2006201020122015201620182019

What are the most-cited papers on Julie R. Brahmer?

ScholarIQmost cited works
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
New England Journal of Medicine. 201212,730 CitationsOPEN ACCESS
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinéad Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A. Leiby, Gregory M. Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R. Brahmer
New England Journal of Medicine. 201610,184 CitationsOPEN ACCESS
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer
New England Journal of Medicine. 20159,504 CitationsOPEN ACCESS
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel
New England Journal of Medicine. 20158,599 CitationsOPEN ACCESS
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, Wen-Jen Hwu, Suzanne L. Topalian, Patrick Hwu, Charles G. Drake, Luis H. Camacho, John Kauh, Kunle Odunsi, Henry C. Pitot, Omid Hamid, Shailender Bhatia, Renato Martins, Keith D. Eaton, Shuming Chen, Theresa M. Salay, Suresh Alaparthy, Joseph F. Grosso, Alan J. Korman, Susan Parker, Shruti Agrawal, S. Goldberg, Drew M. Pardoll, Ashok Gupta, Jon M. Wigginton
New England Journal of Medicine. 20128,040 CitationsOPEN ACCESS

Related on ScholarIQ

Bloomberg (United States)
Institution
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Paper
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Paper
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Paper
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Paper
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Paper
470M+ articles · free account